Current Size: 100%


For further details on the collaborations within the SFB-F61, SFB-F47 or SFB-F28 network grants please follow the links.


Prof. Fritz Aberger, University Salzburg, skin cancer and hedgehog signaling

Dr. Christoph Bock, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, bioinformatics and genexpression analysis

Prof. Thomas Decker, MFPL Vienna, STAT1 in melanoma

Prof. Reinhold Erben, University of Veterinary Medicine, Vienna, Ewing´s sarcoma

Prof. Heinrich Kovar, CCRI Vienna, Ewing´s sarcoma

Dr. Robert Kralovics, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, MPN mouse models

Dr. Stefan Kubicek, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, chemical screening and metabolomics

Prof. Wolfgang Mikulits, Medical University Vienna, liver cancer

Prof. Mathias Müller, University of Veterinary Medicine, Vienna, Tyk2 and transgenesis

Prof. Thomas Rülicke, University of Veterinary Medicine, Vienna, mouse models

Prof. Veronika Sexl, University of Veterinary Medicine, Vienna, JAK-STAT in cancer, CML resistance mechanisms and CDK6

Prof. B. Strobl, University of Veterinary Medicine, Vienna, STAT1 signaling

Prof. Michael Trauner, Medical University Vienna, metabolism and liver cancer

Prof. Peter Valent, Medical University Vienna, MPN and leukemia



Prof. K.D. Bunting, Emory University, Atlanta, USA, interference with inhibitors of the PI3K-AKT-mTOR cascade in neoplastic cells

Prof. S. Constantinescu, Ludwig Cancer Institute, Bruessel, Belgium, p53 mutations and MPN

Prof. M. Deininger, Utah Huntsman CI, Salt Lake City, USA, STAT3/5 in the evolution and progression of CML and targeting them

Prof. K. Friedrich, Institute for Biochemistry, Friedrich Schiller University Jena, Jena, Germany, colorectal cancer

Prof. B. Groner, Georg-Speyer-Haus, Frankfurt, Germany, oncogenic STAT3/5

Prof. P. Gunning, University Toronto, SH2 domain inhibitors

Prof. X. Han, Cincinnati Children's Hospital Medical Center, Cincinnati, USA, and
Key Laboratory of Human Disease Comparative Medicine, Ministry of Health; the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, P.R. China
cytokine signaling in the GI tract for inflammatory and neoplastic disease

Prof. M. Heim and Prof. L. Terracciano, University Hospital Basel, Basel, Switzerland, liver cancer and metabolism

Prof. L. Hennighausen and Prof. J. O´Shea, NIH, Washington, USA, immunity, mouse models of STAT function

Prof. F. Gouilleux, Université Rabelais, Tours, France, STAT5 in leukemogenesis and PI3K-AKT-mTOR signaling

Prof. AT. Look, Dana Farber, Boston, USA, T-cell leukemia and mutated JAK kinases

Prof. G. Müller-Newen, RWTH Aachen, Deutschland, STAT5 shuttling in CML and AML

Prof. W. Priebe, MD Anderson Cancer Center, USA, inhibitors of transcription factors

Prof. W. Tse, James Graham Brown Cancer Center, Louisville, Kentucky, USA, AF1q in MetastasisAF1q in breast cancer metastasis

Prof. J. Tuckermann, University Ulm, Ulm, Germany, GR-STAT5 in hematopoietic cells and for metabolic control

Prof. K.U. Wagner, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, USA, JAK2-STAT5 signaling and transgenic mouse models

Research Groups: